Notably, it has been recently shown that triple inhibition by FULV, CDK4/6i, and AKTi durably impairs BC cell growth, prevents progression, and reduces metastases of tumor xenografts resistant to the combination of CDK4/6i and FULV or FULV alone [104]. Here, CDK4 is linked to neoplasm.